Publications
Find an abstract and a link to most of the publications produced by Nordic Bioscience
Objectives: There is a need for precision medicine and an unspoken promise of an optimal approach for identification of the right patients for value-based medicine based on big data. However, there may be a misconception that measurement of proteins is more valuable than measurement of fewer selecte...
August 26, 2021
Journal:
Clin Biochem
Author:
Karsdal MA, Rasmussen DGK, Bay-Jensen AC, Mortensen JH, Holm Nielsen S, Willumsen N, Jensen C, Manon-Jensen T, Jennings L, Reese-Petersen AL, Henriksen K, Leeming DJ, Bager CL, Genovese F, Bülow Sand JM
Abstract Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity t...
June 21, 2021
Journal:
Elife
Author:
Ramos Pascoal MI, Tian L, de Ruiter EJ, Song C, Paucarmayta A, Singh A, Elshof E, Vivjer SV, Shaik J, Bosiacki J, Cusumano Z, Jensen C, Willumsen N, Karsdal MA, Liu L, Langermann S, Willems S, Flies D, Meyaard L
A desmoplastic colorectal cancer stroma, characterized by excess turnover of the cancer-associated fibroblast derived collagens type III and VI, can lead to reduced drug-uptake and poor treatment response. We investigated the association between biomarkers of collagen type III and VI and overall sur...
January 19, 2021
Journal:
Sci Rep
Author:
Nissen NI, Boisen MK, Liljefors M, Jensen C, Johansen AZ, Johansen JS, Erler JT, Mortensen JH, Høye A, Willumsen N, Karsdal MA, Kehlet SN
Purpose: Non-invasive biomarkers for diagnosing and prognosing hepatocellular carcinoma (HCC) are urgently needed. Cirrhosis is present in 80-90% of HCC patients. Cirrhosis is characterized by deposition and cross-linking of collagens that have crucial roles in HCC initiation and progression. We eva...
November 20, 2020
Journal:
J Hepatocell Carcinoma
Author:
Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N.
Background: Immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor induce a response in only a subgroup of patients with metastatic melanoma. Previous research suggests that transforming growth factor beta signaling and a collagen-rich peritumoral stroma (tumor ...
October 8, 2020
Journal:
J Immunother Cancer
Author:
Hurkmans DP, Jensen C, Koolen SLW, Aerts J, Karsdal MA, Mathijssen RHJ, Willumsen N
A T-cell permissive tumor microenvironment, characterized by the presence of activated T cells and low fibrotic activity is crucial for response to immune checkpoint inhibitors (ICIs). Granzyme B has been shown to promote T-cell migration through the basement membrane by the degradation of type IV c...
September 20, 2020
Journal:
Cancers (Basel)
Author:
Jensen C, Sinkeviciute D, Madsen DH, Önnerfjord P, Hansen M, Schmidt H, Karsdal MA, Svane IM, Willumsen N
BACKGROUND: Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated th...
December 19, 2018
Journal:
Br J Clin Pharmacol
Author:
Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA, Willumsen N
Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have bioma...
July 20, 2018
Journal:
Cancer Med
Author:
Jensen C, Nielsen SH, Mortensen JH, Kjeldsen J, Klinge LG, Harling H, Jørgensen LN, Karsdal MA, Willumsen N, Leeming DJ
Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a n...
November 8, 2017
Journal:
Cancer Immunol Immunother
Author:
Willumsen N, Thomsen LB, Bager CL, Jensen C, Karsdal MA
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
